{
    "2018-08-24": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Merck, Eisai Get EU Approval for Lenvima Label Expansion",
                "features": {
                    "keywords": [
                        "Merck",
                        "Eisai",
                        "EU",
                        "Approval",
                        "Lenvima"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test",
                "features": {
                    "keywords": [
                        "Roche",
                        "FDA",
                        "Approval",
                        "Cobas",
                        "EFGR"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "diagnostics"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "AstraZeneca's Bevespi Unimpressive in Phase III COPD Study",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Bevespi",
                        "Phase III",
                        "COPD",
                        "Unimpressive"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept",
                "features": {
                    "keywords": [
                        "Roche",
                        "Immunology",
                        "Pulmozyme",
                        "CellCept"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-08-27",
                "original_text": "Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 27, 2018",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Ex-Dividend",
                        "Date",
                        "Scheduled"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Roche’s Immunology Drug Actemra: A Long-Term Growth Driver?",
                "features": {
                    "keywords": [
                        "Roche",
                        "Immunology",
                        "Actemra",
                        "Growth",
                        "Driver"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Novartis’s SOLAR-1 Trial Met Primary Endpoint",
                "features": {
                    "keywords": [
                        "Novartis",
                        "SOLAR-1",
                        "Trial",
                        "Primary",
                        "Endpoint"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Swiss Stock Market Clung To A Small Gain After Late Pullback",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock Market",
                        "Small Gain",
                        "Pullback"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "An Update on Roche’s Immunology Drugs: Xolair and Esbriet",
                "features": {
                    "keywords": [
                        "Roche",
                        "Immunology",
                        "Xolair",
                        "Esbriet"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "[$$] Digital therapeutics show potential for healthcare disruption",
                "features": {
                    "keywords": [
                        "Digital",
                        "therapeutics",
                        "healthcare",
                        "disruption"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}